home / stock / govxw / govxw news

GOVXW News and Press, GeoVax Labs Inc. Warrants

Stock Information
Company Name: GeoVax Labs Inc. Warrants
Stock Symbol: GOVXW
Market: NASDAQ
Website: geovax.com
Menu
GOVXW GOVXW Quote GOVXW Short GOVXW News GOVXW Articles GOVXW Message Board
Get GOVXW Alerts

News, Short Squeeze, Breakout and More Instantly...
GOVXW - GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript

2024-05-14 20:01:02 ET GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Conference Call May 14, 2024, 04:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer ...
GOVXW - GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced ...

GOVXW - GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will presen...

GOVXW - GeoVax to Present at the 36th Annual Roth Conference

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36t...
GOVXW - GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against c...

GOVXW - GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of Gedeptin ® , targeting advanced head and neck cancer Catalyst-rich 2024 with data readouts p...

GOVXW - GeoVax to Present at the 2024 BIO CEO & Investor Conference

ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 20...
GOVXW - GeoVax Announces Multiple Patent Issuances and Allowances

Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and...

GOVXW - GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against ca...

GOVXW - GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc.  (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company's Board of Directors has ap...
Next 10